After FDA delay, Arcutis gets Zoryve OK in atopic dermatitis

After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the new indication of atopic dermatitis (AD), a common form of eczema.The FDA had been due to give its verdict on the Zoryve (roflumilast) for the new use on the 7th of this month, but the date came and went. In an unusual attempt to quell shareholder jitters, Arcutis issued a statement yesterday saying there had been no request for new information and it was expecting a letter from the regulator soon.